Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer
Status:
Not yet recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
Pancreatic cancer is one of the leading causes of cancer deaths in the United States with
limited treatment options, especially for those patients with metastatic disease. Combination
treatment with cabozantinib and atezolizumab, has demonstrated safety for the treatment of
other cancers and has shown promise in preclinical studies utilizing patient derived pancreas
organoids. In this study, patients with refractory, metastatic pancreatic cancer will receive
combination cabozantinib + atezolizumab and the efficacy of this treatment will be assessed
through overall response rate (ORR), disease control rate (DCR), median overall survival
(mOS), and median progression free survival (mPFS). Safety and tolerability of combination
cabozantinib plus atezolizumab in metastatic pancreatic cancer patients will also be assessed
and immune profiling pre- and post-treatment will be explored.